The COMPASS trial: practical considerations for application after coronary artery bypass surgery.
Curr Opin Cardiol
; 35(5): 583-588, 2020 09.
Article
em En
| MEDLINE
| ID: mdl-32649352
ABSTRACT
PURPOSE OF REVIEW We review the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial with particular emphasis on patients with a history of remote coronary artery bypass grafting (CABG) and those who were enrolled 4-14 days after CABG. We provide practical guidance for selecting patients with the greatest potential to benefit who have acceptable bleeding risk. In particular, we address concerns about postoperative bleeding and discuss the relative merits of rivaroxaban and aspirin versus P2Y12 inhibition and aspirin. RECENT FINDINGS:
The COMPASS trial demonstrated that rivaroxaban and aspirin reduce myocardial infarction, stroke, and cardiovascular death in patients with coronary artery disease, without a demonstrated effect on bypass graft patency in the first postoperative year.SUMMARY:
After CABG, cardiac surgeons should consider using the COMPASS regimen in patients at high risk of thrombosis whose risk of bleeding is acceptable. If used, the COMPASS regimen should be continued indefinitely in conjunction with other pharmacological risk reduction therapies to prevent long-term atherothrombotic events.
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
6_ODS3_enfermedades_notrasmisibles
Base de dados:
MEDLINE
Assunto principal:
Doença da Artéria Coronariana
/
Ponte de Artéria Coronária
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Revista:
Curr Opin Cardiol
Ano de publicação:
2020
Tipo de documento:
Article